Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Switzerland’s Galderma Pharma have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide. Under the terms of the five-year deal, financial terms of which were not revealed, Galderma – a joint venture of L’Oreal and Nestle – will have exclusive access to a number of compounds from across AstraZeneca’s portfolio to develop in dermatological indications.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.